Copyright
©The Author(s) 2024.
World J Gastroenterol. Oct 7, 2024; 30(37): 4132-4148
Published online Oct 7, 2024. doi: 10.3748/wjg.v30.i37.4132
Published online Oct 7, 2024. doi: 10.3748/wjg.v30.i37.4132
Figure 1 Flow diagram depicting the patients with infiltrative hepatocellular camrelizumab enrolled in the study.
PD1: Programmed cell death protein 1; BMI: Body mass index.
- Citation: Wang YQ, Pan D, Yao ZY, Li YQ, Qu PF, Wang RB, Gu QH, Jiang J, Han ZX, Liu HN. Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy. World J Gastroenterol 2024; 30(37): 4132-4148
- URL: https://www.wjgnet.com/1007-9327/full/v30/i37/4132.htm
- DOI: https://dx.doi.org/10.3748/wjg.v30.i37.4132